Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation

PURPOSE: Cetuximab and panitumumab have an effective therapeutic response in a subset of RAS Wild-Type (WT) metastatic colorectal cancers (mCRCs). Despite molecular-driven selection, all patients do not respond to epidermal growth factor receptor (EGFR) inhibitors and the onset of secondary resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Stefania, Martini, Giulia, Martinelli, Erika, Belli, Valentina, Parascandolo, Alessia, Laukkanen, Mikko O., Sforza, Vincenzo, Morgillo, Floriana, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620195/
https://www.ncbi.nlm.nih.gov/pubmed/28978055
http://dx.doi.org/10.18632/oncotarget.18749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620195/
https://www.ncbi.nlm.nih.gov/pubmed/28978055
http://dx.doi.org/10.18632/oncotarget.18749

Ejemplares similares